How to help your patients find Rexulti in stock: A provider's guide

When a patient calls your office saying their pharmacy can't fill their Rexulti, it's not just an inconvenience — it's a potential clinical event. For patients with schizophrenia or treatment-resistant depression, even a short gap in brexpiprazole therapy can have serious consequences.

This practical guide walks through the most effective steps your practice can take to help patients access Rexulti — from resolving insurance hurdles to identifying reliable pharmacies to enabling real-time stock searches.

Step 1: Understand why the prescription isn't being filled

Before taking action, find out what the actual barrier is. Ask the patient or their pharmacy:

• Is it a stock issue? The pharmacy physically doesn't have the medication or the specific strength.
• Is it an insurance rejection? Prior authorization required, step therapy not yet completed, or formulary non-coverage.
• Is it a cost issue? The patient is uninsured or underinsured and the cash price of $1,500+ is prohibitive.

Each barrier has a different solution. Conflating them wastes time and delays the patient's access to medication.

Step 2: For stock issues — direct patients to Medfinder and large chain pharmacies

If the issue is pharmacy stock, the fastest resolution is a real-time inventory search. Medfinder shows which pharmacies near the patient currently have their specific Rexulti strength in stock. Directing patients to Medfinder eliminates the inefficient phone-tree approach and gets them to the right pharmacy quickly.

For patients who prefer phone guidance, advise them to call large national chains first — CVS, Walgreens, Walmart, and Costco pharmacies have better specialty drug supply chains than independent pharmacies. Have your staff call on the patient's behalf if they're unable to navigate this themselves.

Step 3: For insurance barriers — move fast on prior authorization

Prior authorization is the most common reason Rexulti claims are rejected at the pharmacy counter. Given how frequently Rexulti requires PA, your practice should have a standard workflow in place:

1. Submit PA at the time of prescribing, not after the patient is rejected at the pharmacy.
2. Include documentation of: diagnosis, previous medication trials with outcomes, and the clinical rationale for brexpiprazole specifically.
3. If the initial PA is denied, file an appeal immediately. Peer-to-peer review requests are often more successful than written appeals alone.
4. While the PA is being processed, provide bridge samples from your office stock if available.

Step 4: For cost barriers — connect patients with savings programs

Rexulti's cash price of roughly $1,500–$2,000 per month is a real barrier for uninsured and underinsured patients. Commercially insured patients can use the Rexulti Savings Card (available at rexulti.com/savings-cost), which may reduce out-of-pocket cost to as little as $0 with an annual maximum benefit of $8,180.

For uninsured patients or those who don't qualify for the savings card, the Otsuka Patient Assistance Foundation (OPAF) provides Rexulti at no cost to eligible patients. OPAF is underutilized — many providers don't mention it, and many eligible patients never apply. Contact OPAF at 1-800-441-6763 or through otsukapatientsupport.com/rexulti.

Note: The Rexulti Savings Card cannot be used by patients with Medicare, Medicaid, TRICARE, or other government insurance. Medicare patients may benefit from the Part D Low-Income Subsidy (Extra Help) program for additional cost assistance.

Step 5: Recommend mail-order for stable patients

For patients who have been stable on Rexulti for several months and don't need frequent dose adjustments, mail-order pharmacy is an excellent option. Specialty mail-order pharmacies have more reliable supply chains for brand-name medications and can deliver 90-day supplies directly to the patient's home.

Many insurance plans also offer lower copays on 90-day mail-order supplies. When renewing Rexulti for a stable patient, consider writing a 90-day prescription and routing them to their insurance plan's preferred mail-order pharmacy.

When to consider a therapeutic switch

If access barriers are persistent and cannot be resolved through the steps above, a therapeutic switch may be appropriate. Aripiprazole is the closest pharmacological alternative — it shares brexpiprazole's D2 partial agonist mechanism and is available as an inexpensive, widely-stocked generic. When switching, use gradual cross-titration rather than abrupt discontinuation. See our guide to Rexulti alternatives for a full clinical comparison by indication.

Provider resources summary

• Real-time pharmacy inventory for patients: Medfinder for Providers
• Rexulti Savings Card (commercially insured patients): rexulti.com/savings-cost
• Otsuka Patient Assistance Foundation (uninsured/underinsured): otsukapatientsupport.com/rexulti or 1-833-468-7852
• Medicare Part D Low-Income Subsidy (Extra Help): ssa.gov/extrahelp